Please assess the completion status of the following clinical trial:

Trial Title: DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman ≥ 18 years old~* Brugada syndrome diagnosed with a type 1 ECG either spontaneous or drug-induced~* Electrophysiological study indicated for arrhythmic risk stratification purpose~* Inducibility of a sustained ventricular tachycardia (\> 30 seconds) or ventricular fibrillation requiring defibrillation~* Physical medical examination~* Signed written informed consent~Exclusion Criteria:~* Personal or familial history of epilepsy~* Pregnancy~* Body weight \> 100 kg~* the need of \>1 counter shock for defibrillation~* Alcohol or cocaine consumption during the protocol~* Class I (with the exception of local anaesthesia by lidocaine), II, III and IV antiarrhythmic drugs, antidepressant drugs, ATP dependent potassium channel activators, sultopride not stopped for \> 7 halve-lives~* No medical insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 3,4-Di-amino-Pyridine : a single 20 mg dosing
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).